Amgen Inc (AMGN) 127.09 $AMGN
Final Glance: Biotechnology companies
AP - Wed Aug 06, 5:01PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Midday Glance: Biotechnology companies
AP - Wed Aug 06, 12:23PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Biotech Stock Roundup: Amgen Plans Job Cuts, Regeneron's Eylea Continues to Impress - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 06, 11:00AM CDT
Among the earnings reports, the Ebola outbreak has brought quite a few biotech companies into the limelight for their experimental Ebola disease treatments.
Early Glance: Biotechnology companies
AP - Wed Aug 06, 9:32AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
Amgen's Multiple Myeloma Drug Kyprolis Succeeds - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 05, 5:21PM CDT
Amgen (AMGN) intends to submit regulatory applications based on this study in the first half of 2015.
'Fast Money' Recap: Is Michael Kors Still in Fashion?
at The Street - Tue Aug 05, 4:00AM CDT
The trading panel looked at Michael Kors' earnings, Microsoft, steel stocks and biotechs.
Celebrating 20 Years of The Motley Fool Online
David Gardner and Tom Gardner, The Motley Fool - Motley Fool - Mon Aug 04, 3:01PM CDT
This was written by brothers and Fool co-founders David and Tom Gardner. Twenty years ago today, on Aug. 4, 1994, The Motley Fool was born online. We'd started a year before as a print newsletter for friends and family. It was truly motley:...
Why Amgen (AMGN) Stock Is Up Today
at The Street - Mon Aug 04, 2:15PM CDT
Amgen,(AMGN) stock is up after the company said a late-stage study found that its blood cancer drug helped patients live significantly longer without the disease worsening, compared with standard treatment.
Nasdaq Leads In Quiet Session; Priceline Nears Buy Point
at Investor's Business Daily - Mon Aug 04, 1:53PM CDT
Stocks traded quietly higher in light volume with a little more than one hour remaining in Monday's session. The Nasdaq and S&P led the way, rising 0.5% and 0.4% respectively. The Dow Jones industrial average added 0.2%. Volume on the NYSE and Nasdaq...
Amgen Cancer Drug Kyprolis Succeeds In Trial
at Investor's Business Daily - Mon Aug 04, 9:56AM CDT
Big biotech Amgen (AMGN) early Monday reported positive interim results from a crucial late-stage trial of blood-cancer drug Kyprolis Monday, helping justify its $10 billion acquisition of Onyx last year. Amgen was up more than 1% in early trading in...
Amgen (AMGN) Crosses Pivot Point Resistance at $126.98
Comtex SmarTrend(R) - Mon Aug 04, 9:02AM CDT
Shares of Amgen (NASDAQ:AMGN) have bullishly opened above the pivot of $125.87 today and have reached the first resistance level of $126.98. Should the shares continue to rise, the resistance pivots of $128.41 and $130.95 will be of interest.
S&P Down 3% - What's on Sale? - Ahead of Wall Street
Mark Vickery - Zacks Investment Research - Mon Aug 04, 8:36AM CDT
Solid Q2 earnings across most sectors this season justified the long run-up in the stock market, and we had been expecting stronger quarterly data.
Earnings Headlines - Amgen
PR Newswire - Mon Aug 04, 8:30AM CDT
Investor-Edge.com has issued complimentary earnings coverage on Amgen Inc. (NASDAQ: AMGN) as the company featured in the headlines on Tuesday, July 29, 2014. Amgen Inc. reported 11% Y-o-Y growth in total revenues, while adjusted earnings per share (EPS) increased 25% in the second quarter of 2014, outperforming market expectations. Our free coverage report can be accessed at:
Drug Approvals and Earnings Releases - Research Reports on Bristol-Myers, Johnson & Johnson, Merck, Pharmacyclics and Amgen
PR Newswire - Mon Aug 04, 7:50AM CDT
Today, Analysts Review released its research reports regarding Bristol-Myers Squibb Co. (NYSE: BMY), Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Pharmacyclics Inc. (NASDAQ: PCYC) and Amgen Inc. (NASDAQ: AMGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5355-100free.
Amgen Announces Phase 3 ASPIRE Trial Of Kyprolis® In Patients With Relapsed Multiple Myeloma Met Primary Endpoint
PR Newswire - Mon Aug 04, 6:30AM CDT
Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) met its primary endpoint of progression-free survival (PFS). Patients treated with Kyprolis® (carfilzomib) for Injection in combination with Revlimid® (lenalidomide) and low-dose dexamethasone (KRd) lived significantly longer without their disease worsening (median 26.3 months) compared to patients treated with Revlimid and low-dose dexamethasone (Rd) (median 17.6 months) (HR=0.690, 95 percent CI, 0.570, 0.834, p<0.0001). While the data for overall survival, a secondary endpoint, are not yet mature, the analysis showed a trend in favor of KRd that did not reach statistical significance.
Final Glance: Biotechnology companies
AP - Wed Aug 06, 5:01PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Midday Glance: Biotechnology companies
AP - Wed Aug 06, 12:23PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Biotech Stock Roundup: Amgen Plans Job Cuts, Regeneron's Eylea Continues to Impress - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 06, 11:00AM CDT
Among the earnings reports, the Ebola outbreak has brought quite a few biotech companies into the limelight for their experimental Ebola disease treatments.
Early Glance: Biotechnology companies
AP - Wed Aug 06, 9:32AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
Amgen's Multiple Myeloma Drug Kyprolis Succeeds - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 05, 5:21PM CDT
Amgen (AMGN) intends to submit regulatory applications based on this study in the first half of 2015.
'Fast Money' Recap: Is Michael Kors Still in Fashion?
at The Street - Tue Aug 05, 4:00AM CDT
The trading panel looked at Michael Kors' earnings, Microsoft, steel stocks and biotechs.
Celebrating 20 Years of The Motley Fool Online
David Gardner and Tom Gardner, The Motley Fool - Motley Fool - Mon Aug 04, 3:01PM CDT
This was written by brothers and Fool co-founders David and Tom Gardner. Twenty years ago today, on Aug. 4, 1994, The Motley Fool was born online. We'd started a year before as a print newsletter for friends and family. It was truly motley:...
Why Amgen (AMGN) Stock Is Up Today
at The Street - Mon Aug 04, 2:15PM CDT
Amgen,(AMGN) stock is up after the company said a late-stage study found that its blood cancer drug helped patients live significantly longer without the disease worsening, compared with standard treatment.
Nasdaq Leads In Quiet Session; Priceline Nears Buy Point
at Investor's Business Daily - Mon Aug 04, 1:53PM CDT
Stocks traded quietly higher in light volume with a little more than one hour remaining in Monday's session. The Nasdaq and S&P led the way, rising 0.5% and 0.4% respectively. The Dow Jones industrial average added 0.2%. Volume on the NYSE and Nasdaq...
Amgen Cancer Drug Kyprolis Succeeds In Trial
at Investor's Business Daily - Mon Aug 04, 9:56AM CDT
Big biotech Amgen (AMGN) early Monday reported positive interim results from a crucial late-stage trial of blood-cancer drug Kyprolis Monday, helping justify its $10 billion acquisition of Onyx last year. Amgen was up more than 1% in early trading in...
Amgen (AMGN) Crosses Pivot Point Resistance at $126.98
Comtex SmarTrend(R) - Mon Aug 04, 9:02AM CDT
Shares of Amgen (NASDAQ:AMGN) have bullishly opened above the pivot of $125.87 today and have reached the first resistance level of $126.98. Should the shares continue to rise, the resistance pivots of $128.41 and $130.95 will be of interest.
S&P Down 3% - What's on Sale? - Ahead of Wall Street
Mark Vickery - Zacks Investment Research - Mon Aug 04, 8:36AM CDT
Solid Q2 earnings across most sectors this season justified the long run-up in the stock market, and we had been expecting stronger quarterly data.
Earnings Headlines - Amgen
PR Newswire - Mon Aug 04, 8:30AM CDT
Investor-Edge.com has issued complimentary earnings coverage on Amgen Inc. (NASDAQ: AMGN) as the company featured in the headlines on Tuesday, July 29, 2014. Amgen Inc. reported 11% Y-o-Y growth in total revenues, while adjusted earnings per share (EPS) increased 25% in the second quarter of 2014, outperforming market expectations. Our free coverage report can be accessed at:
Drug Approvals and Earnings Releases - Research Reports on Bristol-Myers, Johnson & Johnson, Merck, Pharmacyclics and Amgen
PR Newswire - Mon Aug 04, 7:50AM CDT
Today, Analysts Review released its research reports regarding Bristol-Myers Squibb Co. (NYSE: BMY), Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Pharmacyclics Inc. (NASDAQ: PCYC) and Amgen Inc. (NASDAQ: AMGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5355-100free.
Amgen Announces Phase 3 ASPIRE Trial Of Kyprolis® In Patients With Relapsed Multiple Myeloma Met Primary Endpoint
PR Newswire - Mon Aug 04, 6:30AM CDT
Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) met its primary endpoint of progression-free survival (PFS). Patients treated with Kyprolis® (carfilzomib) for Injection in combination with Revlimid® (lenalidomide) and low-dose dexamethasone (KRd) lived significantly longer without their disease worsening (median 26.3 months) compared to patients treated with Revlimid and low-dose dexamethasone (Rd) (median 17.6 months) (HR=0.690, 95 percent CI, 0.570, 0.834, p<0.0001). While the data for overall survival, a secondary endpoint, are not yet mature, the analysis showed a trend in favor of KRd that did not reach statistical significance.
